A translational, pharmacodynamic and pharmacokinetic phase IB clinical study of everolimus in resectable non-small cell lung cancer

PURPOSE: Altered PI3K/mTOR pathway is implicated in lung cancer but mTOR inhibitors have failed to demonstrate efficacy in advanced lung cancer. We studied the pharmacodynamic effects of everolimus in resectable non-small cell lung cancer (NSCLC) to inform further development of these agents in lung...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Owonikoko, Taofeek K., Ramalingam, Suresh S., Miller, Daniel L., Force, Seth D., Sica, Gabriel L., Mendel, Jennifer, Chen, Zhengjia, Rogatko, Andre, Tighiouart, Mourad, Harvey, R. Donald, Kim, Sungjin, Saba, Nabil F., Pickens, Allan, Behera, Madhusmita, Fu, Robert W., Rossi, Michael R., Auffermann, William F., Torres, William E., Bechara, Rabih, Deng, Xingming, Sun, Shi-Yong, Fu, Haian, Gal, Anthony A., Khuri, Fadlo R.
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4401630/
https://ncbi.nlm.nih.gov/pubmed/25673697
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-1998
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados